You may also be interested in articles related to Clarient (CLRT):
Nov 30,2009:- Clarient Inc. has signed an exclusive license to technology aimed at making better tests for cancer. The company said it licensed a test that can identify the MUC1 protein from privately held Minerva Biotechnologies. The protein is a potential biomarker that could help identify various types of cancer. Financial terms of the deal were not disclosed. Clarient is the leading medical device maker in MUC1 protein. Clarient is investing in further developing MUC1 protein.